ReviewDrugs in context2021
Dermatology: how to manage acne vulgaris.
Review in Drugs in context, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 58 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
58 citing papers in PubMed, 151 citations in OpenAlex.
- Effect of isotretinoin and omega-3 fatty acid combination on lipid metabolism in patients with acne vulgaris: a randomized controlled trial.Lipids in health and disease · 2026Trial
- Safety and Clinical Efficacy of KūlarisClinical, cosmetic and investigational dermatology · 2025Trial
- Trial
- Therapeutic Journey Among Patients with Acne Treated with Isotretinoin.Dermatology and therapy · 2026Article
- Effectiveness and Tolerability of Low-Dose Micronized Isotretinoin in Patients with Severe Recalcitrant Nodular Facial Acne in India: a Real-World Retrospective Study Using Electronic Medical Records.Dermatology and therapy · 2026Article
- The association betweenJournal of medicine and life · 2026Article
- Iontophoresis-assisted transdermal drug delivery for the treatment of inflammatory dermatoses: A review.Journal of pharmaceutical analysis · 2026Review
- Leciplex Nanocarriers: An Optimized Platform for Thymol Delivery in Acne Management.Pharmaceutics · 2026Article
- Growth-Inhibitory Activity of a Clerodane Diterpene fromACS infectious diseases · 2026Article
- Cellulose Acetate Fibers With Infiltrated ZnO Nanocrystals: Activation of Antibacterial Properties Against Acne vulgaris by Oxygen Plasma Treatment.Small (Weinheim an der Bergstrasse, Germany) · 2026Article
- Personalized Approach for Acne Management With Dermocosmetics According to Initial Skin Sensitivity.Journal of cosmetic dermatology · 2026Observational
- Plant-Based Protein Fermentation Medium Optimization for Antimicrobial Cell-Free Supernatant Production by Lactiplantibacillus plantarum K014 Against Cutibacterium acnes.Probiotics and antimicrobial proteins · 2026Article
- Spatial transcriptomics identifies differentiation, lipid metabolism, and retinoid pathway alterations in acne vulgaris.JCI insight · 2026Article
- A Comprehensive Review of Acne Treatments: Unpacking the Chemical Structures and Effective Bioactive Compounds.Health science reports · 2026Article
- Divergent System Organ Class Safety Profiles of Isotretinoin Versus Topical Retinoids: An EudraVigilance Disproportionality Analysis.Pharmaceuticals (Basel, Switzerland) · 2026Article
- Evaluation of acne vulgaris patient care in outpatient clinics: guideline adherence and patient education.Turkish journal of medical sciences · 2026Observational
- Association of fast foods and dairy products in acne severity and scarring: a cross-sectional study.Annals of medicine and surgery (2012) · 2026Article
- Optimal Use Recommendations and Stewardship Principles with Oral Antibiotics in Acne Vulgaris Management: An Expert Consensus Panel.The Journal of clinical and aesthetic dermatology · 2025Review
- Redefining acne treatment: emerging role of probiotics in dermatology.Archives of microbiology · 2025Review
- Planning and optimizing a digital self-management support intervention: Acne Care Online.British journal of health psychology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAcne vulgaris is the most common skin disease that can lead to disfigurement and psychological distress. This article aims to provide a narrative updated review on the management of acne vulgaris.
methodsA PubMed search was performed with Clinical Queries using the key term "acne". The search strategy included clinical trials, meta-analyses, randomized controlled trials, observational studies and reviews. The search was restricted to articles published in English.
resultsTreatments of acne include proper skin care, topical medications, oral medications and procedural therapies. Topical agents are the first-line treatment for mild-to-moderate acne and can be used as combination therapy for more severe acne. Systemic therapies are usually prescribed for the initial treatment of moderate-to-severe acne as well as for acne that is refractory to topical therapies.
conclusionTopical retinoids are the drugs of choice for the treatment and maintenance therapy of patients with mild-to-moderate acne vulgaris. Depending on the severity of the acne, topical retinoids may be used alone or in combination with benzoyl peroxide and topical or oral antibiotics. Oral antibiotics are an important therapy for inflammatory acne unresponsive to topical therapy. Neither topical nor oral antibiotics should be used as monotherapy. Oral contraceptives and/or spironolactone are useful for many women with acne. Oral isotretinoin is the drug of choice for severe, extensive, nodular acne vulgaris but is also often used in moderate cases where scarring is evident, acne-related psychosocial distress is significant or other treatment modalities have failed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.